Potential mechanisms include impaired Th17 cell numbers and function, increased risk of Type 1 hypersensitivity reactions (IgE mediated) and the production of anti-romosozumab antibodies that may trigger immune complex-mediated reactions. Here, IGHE is linked to IgE responsiveness, atopic.